   Gergel Ivan | | ZoomInfo.com

Ivan P. Gergel Sells 8389 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

































  Notizie
                

Analysts Opinions on: American Axle & Manufacturing Holdings Inc. (AXL) 
Brokerages Set Boohoo.Com PLC (LON:BOO) Price Target at $218.56 
Energy changes will save consumers £40bn in coming decades - Government 
Swedish govt leaks massive trove of citizens' data 
Kinder Morgan (KMI) Given Media Impact Rating of 0.11 
YouTube TV is now live, though only in five major American cities 
InterOcean Capital LLC Buys 33174 Shares of Cisco Systems, Inc. (CSCO) 


























Notizia
Affari Cultura Scienza Sportivo Internazionale Salute Nazionale 




Affari
Cultura
Scienza
Sportivo
Internazionale
Salute
Nazionale


 


Ivan P. Gergel Sells 8389 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
Paterniano Del Favero
Luglio 24, 2017



Condividere













Bank of Montreal Can now owns 8,195 shares of the biopharmaceutical company's stock worth $192,000 after buying an additional 1,464 shares during the period. The Price Index 12m for Nektar Therapeutics (NasdaqGS:NKTR) is 1.46316. Hedge funds and other institutional investors own 93.85% of the company's stock. State Street Corp boosted its position in shares of Nektar Therapeutics by 21.9% in the fourth quarter. Camber Capital Management LLC increased its position in shares of Nektar Therapeutics by 87.5% in the fourth quarter. Municipal Employees Retirement System of MI boosted its position in Nektar Therapeutics by 1.7% in the first quarter.Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Finally, Marshall Wace North America L.P. bought a new position in shares of Nektar Therapeutics during the first quarter worth approximately $23,580,000.Shares of Nektar Therapeutics (NASDAQ NKTR) opened at 22.24 on Friday. The average volume stands around 1.3 million shares. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $24.88. The consensus recommendation for stock is 3.00. State of Alaska Department of Revenue now owns 17,050 shares of the biopharmaceutical company's stock worth $400,000 after buying an additional 460 shares in the last quarter.Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.02. Nektar Therapeutics had a negative net margin of 150.74% and a negative return on equity of 3,072.86%. The company had revenue of $24.73 million during the quarter, compared to the consensus estimate of $29.43 million. Equities research analysts anticipate that Nektar Therapeutics will post ($1.17) earnings per share for the current fiscal year.09/30/2016 - Brean Capital began new coverage on Nektar Therapeutics giving the company a " rating. Equities research analysts expect that Nektar Therapeutics will post ($1.17) EPS for the current year.ILLEGAL ACTIVITY WARNING: This article was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was copied illegally and reposted in violation of USA and worldwide trademark and copyright laws. The original version of this piece of content can be read at https://transcriptdaily.com/2017/07/23/franklin-street-advisors-inc-nc-has-1134000-stake-in-nektar-therapeutics-nasdaqnktr-updated.html.Several research analysts have weighed in on the stock. Jefferies Group LLC upped their price objective on shares of Nektar Therapeutics from $17.00 to $25.00 and gave the stock a "positive" rating in a research note on Tuesday, March 21st. Finally, Piper Jaffray Companies reiterated an "overweight" rating and issued a $29.00 price objective on shares of Nektar Therapeutics in a research note on Tuesday, April 11th. BidaskClub raised Nektar Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday, June 27th. ValuEngine raised shares of Nektar Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, June 2nd. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of "Buy" and an average price target of $26.29.On July 23, 2017, Nektar Therapeutics, a DE corporation ("Nektar"), entered into a License Agreement (the "Agreement") with Eli Lilly and Company, an IN corporation ("Lilly").The Agreement is subject to review by the U. S. Government under the Hart-Scott-Rodino Act (the "HSR Act") and will not become effective until the expiration or earlier termination of the waiting period (or any extension thereof).Either party may terminate the Agreement 120 days after the date of filing under the HSR Act, if the transaction is not effective by that date. The shares were sold at an average price of $21.10, for a total value of $1,158,812.00. Following the completion of the transaction, the chief executive officer now owns 160,884 shares in the company, valued at approximately $3,145,282.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Stephen K. Doberstein sold 1,701 shares of the company's stock in a transaction on Tuesday, May 16th. Following the transaction, the senior vice president now directly owns 32,803 shares in the company, valued at $641,298.65. The disclosure for this sale can be found here. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company's stock valued at $129,000 after buying an additional 535 shares during the last quarter.Nektar Therapeutics is a biopharmaceutical company.The company's immunology pipeline is led by baricitinib, an Incyte co-developed once-daily oral rheumatoid arthritis drug approved in Europe as Olumiant, but whose FDA review ended in April with a Complete Response Letter requesting additional clinical data.

 




Altre relazioni OverNewsmagazine 









24 Luglio 2017




O'Donnell explains NASCAR's late-race timing, decisions at Indy









24 Luglio 2017




Fomento Economico Mexicano SAB de CV







Green Plains, Inc. (GPRE) Shares Bought by Schwab Charles Investment Management Inc











24 Luglio 2017




Meizu PRO 7 al centro di un nuovo video leaked









24 Luglio 2017




Simona Ventura non sposa più Gerò Carraro: novità con Stefano Bettarini







Intrepid Potash, Inc (NYSE:IPI) Short Interest Up 86.8% in June











24 Luglio 2017




Nolan's Dunkirk Wins the Weekend Box Office with $50.5M









24 Luglio 2017




Belen e Stefano, pace social: lei lo segue su Instagram, lui commenta









24 Luglio 2017




Issue Resloved-The customer got the replacement Xiaomi Redmi Note 4









DE Burlo Group Inc. Sells 13028 Shares of Gilead Sciences, Inc. (GILD)









24 Luglio 2017




World's first floating wind farm emerges off coast of Scotland









24 Luglio 2017




Crash Bandicoot N. Sane Trilogy Beats Splatoon 2 In UK Game Charts









Recenti News Articoli


 
Three new toad species discovered in US




 
Memorable moments from Sean Spicer's tenure as Press Secretary




 
'Shrinkflation' has hit over 2500 consumer products over the past five years




Discuti questo articolo








 PIÙ POPOLARE OverNewsmagazine




Harteau: please support Arradondo as new Minneapolis Police Chief


Taliban take control of two districts in Afghanistan



Microsoft's second-generation HoloLens will include a dedicated AI coprocessor



Li Haotong shoots 63 in final round of British Open



'Black Lightning' Casts James Remar & Damon Gupton As Series Regulars, Watch Trailer



Temptation Island 2017: anticipazioni 24 luglio



Japan's Mitsubishi Tanabe Pharma to buy Israeli company NeuroDerm for $1.1 billion



Here's How much Christopher Nolan's Dunkirk Earned At The Indian Box Office!



ONGC deal: Arun Jaitley panel to oversee divestment, says Dharmendra Pradhan



United Kingdom  government to regulate drones and assess drone users







SEGUI I NOSTRI GIORNALE











ULTIME NOTIZIE OverNewsmagazine



 
Analysts Opinions on: American Axle & Manufacturing Holdings Inc. (AXL)


Brokerages Set Boohoo.Com PLC (LON:BOO) Price Target at $218.56


Energy changes will save consumers £40bn in coming decades - Government


Swedish govt leaks massive trove of citizens' data


Kinder Morgan (KMI) Given Media Impact Rating of 0.11


Ford juices up 2018 Mustang with optional 'drag strip' mode


Norway takes lead in race to build autonomous cargo ships


Fidelity National Financial Inc


Macquarie Reiterates Buy Rating for Amazon.com, Inc. (NASDAQ:AMZN)


NeuroDerm Ltd. (NDRM) Coverage Initiated at Deutsche Bank AG







ALTRE NOTIZIE


Scienza
Cultura
Affari









About 105,760 shares traded. Facebook Inc (NASDAQ:FB) has risen 26.75%...









The No. 80 Irving Park and No. 152 Addison buses will also have extra ...









Previously, the company implemented a feature where the device would c...








Capital Management Corp VA now owns 8,163 shares of the financial serv...









The far-reaching range of these deposits, Milliken says, is crucial.  ...












There are just a few hours left of  Love Island  2017 and if you want ...









The movie is about the  Battle of Dunkirk , where ordinary citizens to...









Forse non tutti sanno che il  Gran Maestro , personaggio che fa la sua...









My money's on  Arya  changing her mind and turning back toward King's ...









Naturally, the  La La Land  actor was flattered by the pop star's admi...











Public Employees Retirement System of OH  boosted its position in Amer...









Centurylink Inc (NYSE:CTL) has declined 7.62% since July 24, 2016 and ...









In a trading statement, the energy storage technology company said the...









This network is connected to the European Union's STESTA, which is a E...









Zimmer Partners Lp sold 1.46M shares as Kinder Morgan Inc Del (KMI)'s ...
























© 2017 overnewsmagazine.com, OverNewsmagazine




Sportivo
Scienza
Cultura
Affari


Nazionale
Salute
Internazionale





Edizione

Contatti



















 




   Ivan Gergel | Endo Pharmaceuticals Holdings Inc. | ZoomInfo.com








Ivan P. Gergel M.D. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Ivan P. Gergel M.D.
Senior Vice President, Drug Development and Chief Medical Officer at Nektar Therapeutics


View Full Profile
Are you Ivan P. Gergel M.D.? Claim your profile


 


Sign up for Equilar Atlas and view Ivan P. Gergel M.D.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Ivan P. Gergel M.D.'s  network and community.
												FOLLOW changes in Ivan P. Gergel M.D.'s employment and money-in-motion.
												CONNECT with Ivan P. Gergel M.D. through your network of contacts.
												








Ivan P. Gergel M.D.'s Executive Work History


Current


Senior Vice President, Drug Development and Chief Medical Officer, 
Nektar Therapeutics


Board Member, 
Corium International, Inc.


Past
To view Ivan P. Gergel M.D.'s complete executive work history, sign up now
Education


														 M.D., 
															University of London


Age
56

 
 


Ivan P. Gergel M.D.'s Biography



Ivan P. Gergel, M.D. has served as our Senior Vice President, Drug Development and Chief Medical Officer since May 2014.  From April 2008 through March 2014, Dr. Gergel served as Executive Vice President, Research & Development and Chief Scientific Officer of Endo Pharmaceuticals, a pharmaceutical company.  Prior to joining Endo Pharmaceuticals, he was Senior Vice President of Scientific Affairs and President of the Forest Research Institute of Forest Laboratories Inc. Prior to that, Dr. Gergel served as Vice President and Chief Medical Officer at Forest and Executive Vice President of the Forest Research Institute. He joined Forest in 1998 a ...
(Read More)

			Ivan P. Gergel, M.D. has served as our Senior Vice President, Drug Development and Chief Medical Officer since May 2014.  From April 2008 through March 2014, Dr. Gergel served as Executive Vice President, Research & Development and Chief Scientific Officer of Endo Pharmaceuticals, a pharmaceutical company.  Prior to joining Endo Pharmaceuticals, he was Senior Vice President of Scientific Affairs and President of the Forest Research Institute of Forest Laboratories Inc. Prior to that, Dr. Gergel served as Vice President and Chief Medical Officer at Forest and Executive Vice President of the Forest Research Institute. He joined Forest in 1998 as Executive Director of Clinical Research following nine years at SmithKline Beecham, and was named Vice President of Clinical Development and Clinical Affairs in 1999. Dr. Gergel is a member of the Board of Directors of Corium International, Inc., a commercial-stage biopharmaceutical company.  Dr. Gergel received his M.D. from the Royal Free Medical School of the University of London and an MBA from the Wharton School.
		
Source: Nektar Therapeutics on 03/01/2017
		
	

 






Sign up for Equilar Atlas and view Ivan P. Gergel M.D.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Ivan P. Gergel M.D.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Ivan P. Gergel M.D.'s  network and community.
												FOLLOW changes in Ivan P. Gergel M.D.'s employment and money-in-motion.
												CONNECT with Ivan P. Gergel M.D. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Ivan P. Gergel M.D.


















Ivan P. Gergel M.D.'s Connections (66)





Sign up now to view Ivan P. Gergel M.D.'s 66 connections »









Gil M. Labrucherie
Senior Vice President and Chief Financial Officer, Nektar Therapeutics









Roger H. Kimmel
Chairman of the Board, Endo International plc









William P. Montague
Former Board Member, Endo International plc









Maninder Hora
Senior Vice President, Pharmaceutical Development and Manufacturing Operations, Nektar Therapeutics









Dennis L. Winger
Board Member, Accuray Incorporated









Camille I. Farhat
President, Chief Executive Officer and Director, RTI Surgical, Inc.









Peter D. Staple
Dir., President and Chief Executive Officer, Corium International, Inc.









Edward J. Sweeney
Former Principal Accounting Officer, Endo International plc









Robert B. Chess
Chairman of the Board, Nektar Therapeutics









John Nicholson
Senior Vice President and Chief Operating Officer, Nektar Therapeutics








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Elon R. Musk
CEO and Chairman, Tesla









Daniel A. DeMatteo
Executive Chairman, GameStop Corp.









David J. O'Connor
President and CEO, The Madison Square Garden Company












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

� 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993
















403 - Forbidden: Access is denied.



Server Error


403 - Forbidden: Access is denied.
You do not have permission to view this directory or page using the credentials that you supplied.







Ivan P Gergel - Malvern, PA | Intelius



























Sign In



We found Ivan P Gergel in Malvern, PA


Ivan P Gergel

                                                                           Intelius found that Ivan P Gergel  is  a male between 50 and 60 years old from Malvern, PA.  We have connected them to
                13 addresses,
                15 phones,
                and 3 relatives or associates.
         





Also Known As

Ivan Highley Gergel


Get Report Now

Age

Ivan P Gergel is in his 50s

Ivan Has Lived In

Malvern, PA
Berwyn, PA
Armonk, NY

Ivan's Relatives

Ann Gergel
Highley Ann
Peter Ond







Ivan P Gergel



Zodiac SignAries



GenderMale



Professional Status
Senior Vice President Drug Development and Chief Medical Officer at Nektar Therapeutics



Get Report Now










Want to know more about Ivan? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Ivan, or use our people search engine to find others.
Get Background Check on Ivan P Gergel
Get a Criminal Check on Ivan P Gergel
Get a Public Record Report on Ivan P Gergel
Get a People Search Report on Ivan P Gergel


Ivan P Gergel's Contact Information
Known Cities Lived In
Find out where Ivan P Gergel has lived as well as Ivan P Gergel's phone numbers and email addresses.




Ivan P Gergel Has Lived in 4 States
Pennsylvania Address for Ivan P Gergel


1352 L* B********* R* 

Malvern, PA


Has Lived In

Malvern, PA
Berwyn, PA


Get Full Address Report










Phone Numbers Associated with Ivan P Gergel

(484) ***-**** - Malvern, PA 
(202) ***-**** - Washington, DC 
(610) ***-**** - Chadds Ford, PA 


Get Full Phone Report



Email Addresses Associated with Ivan P Gergel

g********n@***.com
i*****l@***.com
g******i@***.com


Get Email Report




Ivan P Gergel's Professional Information
Information regarding Ivan P Gergel's professional history.  Find out previous places Ivan P Gergel has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Ivan P Gergel Has Worked at 7 Places
Company: Nektar Therapeutics
               Title: Senior Vice President Drug Development and Chief Medical Officer
Company: Endo Pharmaceuticals
               Title: Executive Vice President - Research & Development, Chief Scientific Officer, Endo Pharmaceuticals
Ivan P Gergel's Experience
Title: Senior Vice President Drug Development and Chief Medical Officer
               Company: Nektar Therapeutics
Job Details
               Company Size: $100 mil to less than $250 mil - Employee Range: 100 to less than 500
Title: Executive Vice President - Research & Development, Chief Scientific Officer, Endo Pharmaceuticals
               Company: Endo Pharmaceuticals
Job Details
               Company Size: $1 bil and above - Employee Range: 1,000 to less than 5,000
Additional Professional Information on Ivan P Gergel

 See Ivan P Gergel's LinkedIn Profile



Ivan P Gergel's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Ivan P Gergel


Ivan P Gergel's known Social Networks And Potential Email Matches

Find all of Ivan P Gergel's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Ivan Gergel
Username Matches

                  IvanGergel
                  GergelIvan
                  Ivan.Gergel
                  Gergel.Ivan
                  Ivan_Gergel
                  Gergel_Ivan
                  Ivan-Gergel
                  Gergel-Ivan
                  IGergel
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
I Gergel







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











﻿




























Ivan P. Gergel Sells 54,920 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - StockNewsTimes














































 















 



  
 
  





















Daily Ratings & News for Nektar Therapeutics
        	Complete the form below to receive the latest headlines and analysts' recommendationsfor Nektar Therapeutics with our free daily email newsletter:



 






Follow @StockNewTimes









Recent Posts

Brokerages Expect Hewlett Packard Enterprise Company (HPE) Will Post Earnings of $0.26 Per Share
Hewlett Packard Enterprise Company (HPE) Expected to Announce Quarterly Sales of $7.56 Billion
Zacks: Brokerages Expect Aduro Biotech, Inc. (ADRO) to Announce -$0.36 EPS
Ryerson Holding Corporation (RYI) Expected to Post Earnings of $0.07 Per Share
athenahealth, Inc. (NASDAQ:ATHN) Rating Increased to B- at TheStreet
-$0.50 EPS Expected for Leap Therapeutics, Inc. (NASDAQ:LPTX) This Quarter
EQT Midstream Partners, LP (NYSE:EQM) Upgraded to “B-” at TheStreet
Philip Morris International Inc (NYSE:PM) Rating Increased to B- at TheStreet
First Solar, Inc. (NASDAQ:FSLR) Upgraded by TheStreet to “C”
athenahealth, Inc. (NASDAQ:ATHN) Upgraded by TheStreet to B-
Wayfair (W) vs. Amazon.com (AMZN) Financial Comparison
Companhia de saneamento Basico Do Estado De Sao Paulo – Sabesp (SBS) versus California Water  Service Group Holding (CWT) Head-To-Head Comparison
Magna International (MGA) & Tenneco (NYSE:TEN) Head to Head Analysis
Contrasting Treehouse Foods (THS) and J.M. Smucker Company (The) (SJM)
Critical Survey: A.H. Belo Corporation (AHC) and Lee Enterprises, (NYSE:LEE)
Ally Financial Inc. (NYSE:ALLY) Upgraded to B- by TheStreet
Polaris Industries Inc. (PII) Upgraded at TheStreet
$31.37 Million in Sales Expected for Summit Therapeutics PLC (NASDAQ:SMMT) This Quarter
Rayonier Inc. (RYN) Receives $29.00 Average Target Price from Brokerages
Zacks: Analysts Expect Cellectis S.A. (CLLS) to Announce -$0.59 EPS



 


Ivan P. Gergel Sells 54,920 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

					Posted by Mandy Boone on Jul 23rd, 2017 // No Comments 



Nektar Therapeutics (NASDAQ:NKTR) SVP Ivan P. Gergel sold 54,920 shares of the business’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $21.10, for a total transaction of $1,158,812.00. Following the completion of the sale, the senior vice president now owns 98,492 shares in the company, valued at $2,078,181.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 
Nektar Therapeutics (NKTR) opened at 22.24 on Friday. The company’s 50 day moving average is $19.64 and its 200-day moving average is $17.47. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $24.88. The stock’s market capitalization is $3.45 billion. 


 Get Nektar Therapeutics alerts:



Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. Nektar Therapeutics had a negative return on equity of 3,072.86% and a negative net margin of 150.74%. The firm had revenue of $24.73 million for the quarter, compared to analyst estimates of $29.43 million. During the same quarter in the previous year, the business posted ($0.14) earnings per share. Nektar Therapeutics’s revenue for the quarter was down 58.0% on a year-over-year basis.  Analysts forecast that  Nektar Therapeutics will post ($1.17) earnings per share for the current fiscal year. 
ILLEGAL ACTIVITY WARNING: This report was first  posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://stocknewstimes.com/2017/07/23/ivan-p-gergel-sells-54920-shares-of-nektar-therapeutics-nasdaqnktr-stock.html. 




A number of large investors have recently added to or reduced their stakes in NKTR. Rothschild Capital Partners LLC purchased a new stake in  Nektar Therapeutics during the second quarter valued at about $1,170,000.  Harvey Capital Management Inc. boosted its stake in  Nektar Therapeutics by 1.1% in the second quarter. Harvey Capital Management Inc. now owns 288,250 shares of the biopharmaceutical company’s stock valued at $5,635,000 after buying an additional 3,200 shares during the last quarter.  Aperio Group LLC boosted its stake in  Nektar Therapeutics by 11.0% in the second quarter. Aperio Group LLC now owns 43,347 shares of the biopharmaceutical company’s stock valued at $847,000 after buying an additional 4,290 shares during the last quarter.  Louisiana State Employees Retirement System boosted its stake in  Nektar Therapeutics by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock valued at $1,236,000 after buying an additional 500 shares during the last quarter.  Finally, LS Investment Advisors LLC boosted its stake in  Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares during the last quarter. Hedge funds and other institutional investors own  93.85% of the company’s stock. 
NKTR has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 27th. Aegis boosted their target price on shares of Nektar Therapeutics from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, April 6th. Piper Jaffray Companies  restated an “overweight” rating and issued a $29.00 target price on shares of Nektar Therapeutics in a report on Tuesday, April 11th. Jefferies Group LLC  set a $25.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Saturday, April 22nd. Finally, Roth Capital  set a $31.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 11th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $26.29.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.







Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



 



 























Latest News





Leave a Reply

Click here to cancel reply.




Name  (Required) 



Mail (will not be published)  (Required) 



Website








 


 

 











































Page Not Found - Leadership Directories
























Products


Blogs


About 


Client Support


Order













Return Home    
        Contact Us


 




                Toll free: 1-800-627-0311

                1407 Broadway, Suite 318, New York, NY 10018
Tel: (212) 627-4140     Fax: (212) 645-0931
            

                1667 K Street, NW, Suite 801, Washington, DC 20006
Tel: (202) 347-7757       Fax:
                (202) 628-3430
            




Terms of use

|

Privacy Policy

|

FAQ

|

Contact us


 ©  Leadership Directories, Inc.
            















 


